Heart Failure Patients Gain New Sleep Apnea Treatment
Updated clinical guidelines now allow for adaptive servo-ventilation use in specific heart failure cases.
Updated on Oct. 15, 2026 in Heart Disease
Live Poll
Do you feel more confident in medical device treatments when clinical guidelines are periodically updated?
The American Academy of Sleep Medicine and European Respiratory Society released updated 2025 guidelines for managing central sleep apnea in heart failure patients. The new clinical advice lifts a prior prohibition against using adaptive servo-ventilation, provided clinicians follow specific stepped management protocols.
Why it matters
Previous concerns about adaptive servo-ventilation stemmed from a 2015 trial that linked the device to increased cardiovascular mortality. Newer meta-analyses and clinical trials have failed to replicate those risks, prompting health authorities to restore it as a treatment option for specific patients.
Updated guidelines follow meta-analyses and trials like CAT-HF and ADVENT-HF, which failed to reproduce the mortality signals reported in the 2015 SERVE-HF study. These findings support the restricted use of adaptive servo-ventilation, while noting that CPAP successfully resolves central sleep apnea in 50% of heart failure patients.
The players
American Academy of Sleep Medicine
A professional society focused on the advancement of sleep medicine and the treatment of sleep disorders.
European Respiratory Society
An international organization that develops clinical guidance for respiratory and sleep-related health conditions.
The details
Clinicians are now advised to follow a stepped approach, using CPAP as the first-line treatment for predominant central sleep apnea before considering adaptive servo-ventilation. When transition to adaptive servo-ventilation is required, it must be initiated under supervision in specialized hospital or sleep center settings. The guidelines strictly prohibit using bilevel PAP in spontaneous mode without a backup rate for these patients, and limit adaptive servo-ventilation to those with a left ventricular ejection fraction between 30% and 45%, or as a palliative measure for those below 30%.
Timeline
2015: The SERVE-HF trial indicated increased cardiovascular mortality with ASV.
2017: The CAT-HF trial was published.
2023: The ADVENT-HF trial was published.
2025: New clinical practice guidelines were issued.
2026: Guidelines are scheduled for presentation at the ERS International Congress.
Health Landscape
These guidelines update the clinical standard of care following the impact of the 2015 SERVE-HF trial. The field is shifting toward a more nuanced risk-benefit assessment rather than a total prohibition on adaptive ventilation devices.
If you are managing heart failure and central sleep apnea, these updates may change how your doctor approaches your breathing support. It is worth discussing with your physician whether your current treatment plan aligns with these new guidelines regarding CPAP trials and specialized oversight for adaptive devices.
The takeaway
The clinical consensus on adaptive servo-ventilation has evolved from a total ban to a guided, risk-stratified approach. If you are currently receiving treatment for central sleep apnea alongside heart failure, talk to your cardiologist about the current guidelines for specialized device management.
Further reading
For more information on managing conditions affecting cardiac health, visit our section on Heart Disease.
Source note: This article includes information reported by Medscape.
Live Poll
Do you feel more confident in medical device treatments when clinical guidelines are periodically updated?
